ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q2 2025 · 99 positions · Total reported value $3.82B · Top-10 concentration 51.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 60.6% · 34 new · 29 cut · 23 exited

Active Share (vs S&P 500): 96.6% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +11.1% · vs SPY -3.7% · Prev Value $4.84B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2025 13F filing, ORBIMED ADVISORS LLC disclosed 99 equity positions with a combined reported value of $3.82B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were SVA ($334.00M), BSX ($302.17M), LLY ($263.17M). By sector, the heaviest allocations are Health Care 83.4%, Industrials 0.5%. Versus the prior quarter, allocation shifted toward Other (+0.7pp) and away from Industrials (-1.1pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 34 new positions, trimmed 29 and fully exited 23, a turnover rate of 60.6% of positions. The portfolio's overlap with the prior quarter was 69% of names.

The largest new positions opened in Q2 2025 were CAI ($81.09M), ROIV ($31.32M), CTMX ($19.21M).

Of the 23 positions fully exited versus the prior quarter, the largest were IONS ($76.64M), XTNT ($34.36M), GILD ($22.13M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • CAI CARIS LIFE SCIENCES INC · $81.09M
  • ROIV ROIVANT SCIENCES LTD SHS · $31.32M
  • CTMX CYTOMX THERAPEUTICS INC · $19.21M
  • MLYS MINERALYS THERAPEUTICS INC COM · $10.29M
  • CPRX CATALYST PHARMACEUTICALS INC · $9.05M
  • ZLAB ZAI LAB LTD ADR · $8.08M
  • AZN ASTRAZENECA PLC · $6.99M
  • ITOS ITEOS THERAPEUTICS INC · $6.98M

Fully Exited (vs previous quarter)

  • IONS Ionis Pharmaceuticals Inc · prev qtr: $76.64M
  • XTNT XTANT MED HLDGS INC · prev qtr: $34.36M
  • GILD GILEAD SCIENCES INC · prev qtr: $22.13M
  • VSTM VERASTEM INC COM NEW · prev qtr: $17.26M
  • AMGN AMGEN INC · prev qtr: $13.77M
  • PFE PFIZER INC · prev qtr: $12.67M
  • VERA VERA THERAPEUTICS INC CL A · prev qtr: $11.56M
  • SLRN ACELYRIN INC · prev qtr: $9.88M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

Sector Allocation

Health Care 83.4%
Other 16.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 2.72M $334.00M 8.73%
8.73%
Hold
2 2.81M $302.17M 7.90%
7.90%
Hold
3 337.60K $263.17M 6.88%
6.88%
Hold
4 15.52M $203.45M 5.32%
5.32%
Add
5 7.96M $159.67M 4.17%
4.17%
Hold
6 291.00K $158.13M 4.13%
4.13%
Hold
7 8.29M $144.63M 3.78%
3.78%
Hold
8 359.20K $142.11M 3.72%
3.72%
Hold
9 1.71M $133.58M 3.49%
3.49%
Add
10 208.00K $114.65M 3.00%
3.00%
Add
11 341.90K $111.49M 2.92%
2.92%
Reduce
12 593.43K $100.25M 2.62%
2.62%
Add
13 210.29K $93.62M 2.45%
2.45%
Add
14 465.00K $81.84M 2.14%
2.14%
Hold
15 3.03M $81.09M 2.12%
2.12%
New
16 1.42M $74.94M 1.96%
1.96%
Hold
17 3.03M $65.90M 1.72%
1.72%
Hold
18 3.70M $64.28M 1.68%
1.68%
Hold
19 5.69M $62.52M 1.64%
1.64%
Hold
20 438.54K $55.12M 1.44%
1.44%
Reduce
21 433.40K $53.30M 1.39%
1.39%
Reduce
22 1.81M $51.49M 1.35%
1.35%
Hold
23 2.58M $48.54M 1.27%
1.27%
Reduce
24 4.00M $45.67M 1.19%
1.19%
Hold
25 427.90K $44.67M 1.17%
1.17%
Add
26 15.22M $39.57M 1.03%
1.03%
Reduce
27 1.08M $35.58M 0.93%
0.93%
Reduce
28 1.15M $33.05M 0.86%
0.86%
Add
29 607.32K $32.27M 0.84%
0.84%
Reduce
30 5.78M $31.38M 0.82%
0.82%
Hold
31 2.78M $31.32M 0.82%
0.82%
New
32 947.88K $29.67M 0.78%
0.78%
Hold
33 2.61M $29.12M 0.76%
0.76%
Reduce
34 7.17M $28.66M 0.75%
0.75%
Add
35 7.56M $28.21M 0.74%
0.74%
Hold
36 1.21M $27.96M 0.73%
0.73%
Add
37 1.20M $24.87M 0.65%
0.65%
Add
38 6.06M $23.09M 0.60%
0.60%
Hold
39 8.46M $19.21M 0.50%
0.50%
New
40 46.50K $18.85M 0.49%
0.49%
Reduce
41 557.90K $18.56M 0.48%
0.48%
Add
42 3.31M $18.10M 0.47%
0.47%
Add
43 5.91M $15.83M 0.41%
0.41%
Reduce
44 248.51K $15.70M 0.41%
0.41%
Reduce
45 50.00K $15.60M 0.41%
0.41%
Reduce
46 1.20M $15.48M 0.41%
0.41%
Add
47 1.92M $14.49M 0.38%
0.38%
Hold
48 1.02M $13.60M 0.36%
0.36%
Hold
49 1.64M $13.14M 0.34%
0.34%
Reduce
50 12.05M $13.13M 0.34%
0.34%
Hold

FAQ

What did ORBIMED ADVISORS LLC buy in 2025-Q2?

In its 2025-Q2 13F filing, ORBIMED ADVISORS LLC reported 99 equity positions worth $3.82B in aggregate; its largest disclosed positions were SVA ($334.00M), BSX ($302.17M), LLY ($263.17M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $3.82B of long equity holdings across 99 positions as of 2025-Q2. Top-10 holdings account for 51.1% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →